Insider Title Company Date Price Return Shares Value
Pierce Christopher EVP and Chief of Business Oper Prelude Therapeutics Inc (PRLD) 2020-09-29 $19.00 -74.7% 3,750 $71,250
Return Profit / (loss) Cost
Total -74.7% $-53,213 $71,250